253 related articles for article (PubMed ID: 28804788)
1. Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS).
Blum K; Febo M; Fried L; Baron D; Braverman ER; Dushaj K; Li M; Demetrovics Z; Badgaiyan RD
J Reward Defic Syndr Addict Sci; 2017; 3(1):3-13. PubMed ID: 28804788
[TBL] [Abstract][Full Text] [Related]
2. Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial.
Blum K; Febo M; Badgaiyan RD
Austin Addict Sci; 2016; 1(2):. PubMed ID: 27840857
[TBL] [Abstract][Full Text] [Related]
3. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
[TBL] [Abstract][Full Text] [Related]
4. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Blum K; Febo M; Fried L; Li M; Dushaj K; Braverman ER; McLaughlin T; Steinberg B; Badgaiyan RD
Subst Use Misuse; 2017 Mar; 52(4):535-547. PubMed ID: 28033474
[TBL] [Abstract][Full Text] [Related]
5. A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".
Blum K; Steinberg B; Gondre-Lewis MC; Baron D; Modestino EJ; Badgaiyan RD; Downs BW; Bagchi D; Brewer R; McLaughlin T; Bowirrat A; Gold M
Psychol Res Behav Manag; 2021; 14():2115-2134. PubMed ID: 34949945
[TBL] [Abstract][Full Text] [Related]
6. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
Gold MS; Baron D; Bowirrat A; Blum K
J Neurol Sci; 2020 Nov; 418():117137. PubMed ID: 32957037
[TBL] [Abstract][Full Text] [Related]
7. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.
Blum K; Bowirrat A; Braverman ER; Baron D; Cadet JL; Kazmi S; Elman I; Thanos PK; Badgaiyan RD; Downs WB; Bagchi D; Llanos-Gomez L; Gold MS
Int J Environ Res Public Health; 2021 Nov; 18(21):. PubMed ID: 34770047
[TBL] [Abstract][Full Text] [Related]
8. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
Blum K; Baron D; McLaughlin T; Gold MS
J Neurol Sci; 2020 Apr; 411():116733. PubMed ID: 32088516
[TBL] [Abstract][Full Text] [Related]
9. Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term.
Blum K; Badgaiyan RD; Braverman ER; Dushaj K; Li M; Thanos PK; Demetrovics Z; Febo M
J Reward Defic Syndr Addict Sci; 2016; 2(1):14-21. PubMed ID: 28317038
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry.
Blum K; Ashford JW; Kateb B; Sipple D; Braverman E; Dennen CA; Baron D; Badgaiyan R; Elman I; Cadet JL; Thanos PK; Hanna C; Bowirrat A; Modestino EJ; Yamamoto V; Gupta A; McLaughlin T; Makale M; Gold MS
J Neurol Sci; 2023 Oct; 453():120809. PubMed ID: 37774561
[TBL] [Abstract][Full Text] [Related]
11. Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?
Blum K; Gold M; Modestino EJ; Baron D; Boyett B; Siwicki D; Lott L; Podesta A; Roy AK; Hauser M; Downs BW; Badgaiyan RD
J Syst Integr Neurosci; 2018 May; 4():. PubMed ID: 31750006
[TBL] [Abstract][Full Text] [Related]
12. Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity.
Blum K; Febo M; Badgaiyan RD; Braverman ER; Dushaj K; Li M; Demetrovics Z
Curr Pharm Des; 2016; 22(38):5837-5854. PubMed ID: 27510492
[TBL] [Abstract][Full Text] [Related]
13. Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual.
Blum K; Lott L; Baron D; Smith DE; Badgaiyan RD; Gold MS
J Syst Integr Neurosci; 2020 May; 7():. PubMed ID: 32934823
[TBL] [Abstract][Full Text] [Related]
14. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.
Blum K; Modestino EJ; Neary J; Gondré-Lewis MC; Siwicki D; Moran M; Hauser M; Braverman ER; Baron D; Steinberg B; Laughlin TM; Badgaiyan RD
Biomed J Sci Tech Res; 2018 Jan; 2(2):1-4. PubMed ID: 30370423
[TBL] [Abstract][Full Text] [Related]
15. Overcoming reward deficiency syndrome by the induction of "dopamine homeostasis" instead of opioids for addiction: illusion or reality?
Blum K; Soni D; Badgaiyan RD; Baron D
J Osteopath Med; 2022 Apr; 122(7):333-337. PubMed ID: 35411759
[TBL] [Abstract][Full Text] [Related]
16. Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-Induced Hyperalgesia.
Brewer R; Blum K; Bowirrat A; Modestino EJ; Baron D; Badgaiyan RD; Moran M; Boyett B; Gold MS
Curr Psychopharmacol; 2020; 9(3):164-184. PubMed ID: 37361136
[TBL] [Abstract][Full Text] [Related]
17. Proposing FDA consideration for the treatment and prophylaxis of opioid and psychostimulant abuse to incorporate the induction of DNA guided dopamine homeostasis: Anti-reward deficiency restoration solution (ARDS).
Blum K; Giordano J; Baron D; McLaughlin T; Badgaiyan RD
J Syst Integr Neurosci; 2020; 8():. PubMed ID: 36407844
[TBL] [Abstract][Full Text] [Related]
18. Addiction Treatment in America: After Money or Aftercare?
Miller D; Miller M; Blum K; Badgaiyan RD; Febo M
J Reward Defic Syndr; 2015 Oct; 1(3):87-94. PubMed ID: 26835513
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.
Blum K; Modestino EJ; Badgaiyan RD; Baron D; Thanos PK; Elman I; Siwicki D; Febo M; Gold MS
EC Psychol Psychiatr; 2018 Aug; 7(8):564-579. PubMed ID: 30417173
[TBL] [Abstract][Full Text] [Related]
20. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.
Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS
J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
